



Matching each patient's  
critical condition to the right  
treatment at the right time

Investor Introduction



MD 676255



# Clinical diagnostic testing: 6.4% CAGR

## Laboratory tests

- delayed diagnosis
- high fixed costs



## Portable Near Patient tests

- 10% CAGR
- not fully quantitative
- unsuited to all human samples



# AgPlus Agilis Reader and Cartridge



Meets unmet need in critical decision areas that cannot be solved with existing products

- 10 mins to result
- fully quantitative
- uses all human samples
- high sensitivity
- growing IP portfolio

= Agilis  
Reader


The logo for the Agilis Reader, featuring the word "Agilis" in a large, black, serif font, with "Reader" in a smaller, blue, sans-serif font below it. To the right of the text is a graphic of a cluster of blue dots of varying sizes, with a larger dot at the top right.



## The problem: COVID-19

- Antibody tests: lateral flow specificity too low
- Antigen tests: all currently run in sterile laboratories where turnaround time is too slow

**Unmet need for high accuracy electrochemical tests that run in <10 mins near patient with both specificity and sensitivity >98%**



# The Problem: AMR

- 50% of antibiotic prescriptions are unnecessary
- By 2050 over 10 million people will die from Anti Microbial Resistance
- PCT Lab testing is effective but takes time and money
- CRP tests are near patient but not sensitive or specific
- Need for an accurate, quantitative rule in rule out test for antibiotics near patient at initial consultation

**Market space available for disruption with a rapid test distinguishing between viral and bacterial infections**





# Business model



Margins grow over time due to greater proportion of high margin activity and lower fixed costs

Revenue Stream	Margin	Drivers	% Revenue 2020	% Revenue 2024
<b>R&amp;D</b>	Mid	Fee for service	42.5%	3.5%
<b>Manufactured Products</b>	Variable	Volume	12.3%	79.9%
<b>License and Royalty</b>	High	Volume	0%	13.4%
<b>Reader Maintenance</b>	Mid	Volume / failure rate	0.1%	2.8%
<b>Grant</b>	Low	% of costs	45%	0.3%

£'000	2019	2020	2021	2022	2023	2024
<b>Revenue</b>	609	1,573	3,695	8,533	16,863	28,828
<b>EBITDA</b>	(563)	(776)	47	1,999	5,597	10,700

# Complementary key team



Christopher Getley  
Chairman



Fiona Marshall  
CEO



Dave Yallop  
Operations Director



Rashesh Joshi  
Part Time FD



Dr Tito Bacarese-Hamilton,  
Scientific Advisory Board Member




Professor Per Venge,  
Scientific Advisory Board Member




UPPSALA  
UNIVERSITET

# Development timeline





# The Ask



AgPlus looks forward to engaging with investors to complete this financing



Thank you

